Ono Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Ono Pharmaceutical has a total shareholder equity of ¥821.5B and total debt of ¥142.5B, which brings its debt-to-equity ratio to 17.3%. Its total assets and total liabilities are ¥1,082.3B and ¥260.8B respectively. Ono Pharmaceutical's EBIT is ¥87.9B making its interest coverage ratio -42.5. It has cash and short-term investments of ¥170.8B.
Key information
17.3%
Debt to equity ratio
JP¥142.50b
Debt
| Interest coverage ratio | -42.5x |
| Cash | JP¥170.84b |
| Equity | JP¥821.50b |
| Total liabilities | JP¥260.81b |
| Total assets | JP¥1.08t |
Recent financial health updates
Is Ono Pharmaceutical (TSE:4528) A Risky Investment?
Nov 25
We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt
Aug 25Recent updates
Earnings Miss: Ono Pharmaceutical Co., Ltd. Missed EPS By 40% And Analysts Are Revising Their Forecasts
Feb 05The Market Doesn't Like What It Sees From Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Earnings Yet
Dec 16Is Ono Pharmaceutical (TSE:4528) A Risky Investment?
Nov 25Ono Pharmaceutical Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 03We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt
Aug 25Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 04There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings
Jun 24Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00
Mar 04Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?
Feb 27Financial Position Analysis
Short Term Liabilities: 4528's short term assets (¥431.9B) exceed its short term liabilities (¥121.8B).
Long Term Liabilities: 4528's short term assets (¥431.9B) exceed its long term liabilities (¥139.0B).
Debt to Equity History and Analysis
Debt Level: 4528 has more cash than its total debt.
Reducing Debt: 4528's debt to equity ratio has increased from 0% to 17.3% over the past 5 years.
Debt Coverage: 4528's debt is well covered by operating cash flow (65%).
Interest Coverage: 4528 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/13 15:10 |
| End of Day Share Price | 2025/02/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ono Pharmaceutical Co., Ltd. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |